Operational Costs Compared: SG&A Analysis of AbbVie Inc. and Vericel Corporation

SG&A Expenses: AbbVie vs. Vericel Over a Decade

__timestamp	AbbVie Inc.	Vericel Corporation
Wednesday, January 1, 2014	7724000000	13774000
Thursday, January 1, 2015	6387000000	22479000
Friday, January 1, 2016	5855000000	27388000
Sunday, January 1, 2017	6275000000	35610000
Monday, January 1, 2018	7399000000	49007000
Tuesday, January 1, 2019	6942000000	61139000
Wednesday, January 1, 2020	11299000000	68836000
Friday, January 1, 2021	12349000000	97592000
Saturday, January 1, 2022	15260000000	106903000
Sunday, January 1, 2023	12872000000	120998000
Monday, January 1, 2024	14752000000

Unleashing insights

A Decade of SG&A: AbbVie Inc. vs. Vericel Corporation

In the ever-evolving pharmaceutical landscape, operational efficiency is paramount. Over the past decade, AbbVie Inc. and Vericel Corporation have showcased contrasting trajectories in their Selling, General, and Administrative (SG&A) expenses. AbbVie, a titan in the industry, saw its SG&A expenses grow by approximately 66% from 2014 to 2023, peaking in 2022. This reflects its expansive operations and strategic investments. In contrast, Vericel, a smaller player, experienced a staggering 780% increase in the same period, highlighting its aggressive growth strategy. By 2023, Vericel's SG&A expenses were still only about 1% of AbbVie's, underscoring the scale difference. This analysis offers a window into how these companies allocate resources to maintain competitiveness and drive innovation.

Published by

U.S. Securities and Exchange Commission

Source link

sec.gov

Date published

17 Jan 2025